

1 **COMPENSATED HYPOGONADISM IN MEN WITH SICKLE CELL DISEASE**

2

3

Anna Paloma Martins Rocha Ribeiro¹

4

Carolina Santos Silva

5

Jean Carlos Zambrano

6

Juliana de Oliveira Freitas Miranda

7

Carlos Augusto Fernandes Molina

8

Cristiano Mendes Gomes

9

Eduardo de Paula Miranda

10

José de Bessa Júnior²

11

12 1. Department of Public Health and Epidemiology, Feira de Santana, Bahia,
13 Brazil.

14 Division of Hematology, Medical School, State University of Feira de Santana,
15 Feira de Santana, Bahia, Brazil

16 2. Division of Urology, Medical School, São Paulo University, Sao Paulo, Sao
17 Paulo, Brazil

18

19 3. Department of Surgery, Ribeirao Preto Medical School, University of Sao
20 Paulo, Ribeirao Preto, Sao Paulo, Brazil

21

22 4. Division of Urology, Medical School, Federal University of Ceara, Fortaleza,
23 Ceara, Brazil

24 5. Division of Urology, Medical School, State University of Feira de Santana,
25 Feira de Santana, Bahia, Brazil

26

28 **ABSTRACT**

29

30 **Introduction:** Sickle cell disease (SCD) is associated with the development of
31 hypogonadism, but there is still controversy regarding its etiology and clinical
32 implications. **Objective:** To evaluate the prevalence of hypogonadism in a population
33 of men with SCD and characterize its etiology. **Methods:** We performed a cross-
34 sectional study of 34 men with SCD aged > 18 years. Sociodemographic and clinical
35 data, including anthropometric measurements (weight, height, and BMI), were
36 obtained. Early morning blood samples were collected and total testosterone (TT),
37 free testosterone (FT), luteinizing hormone (LH), follicle-stimulating hormone (FSH),
38 a complete blood count, and hemoglobin electrophoresis were measured. **Results:**
39 Median age was 33 [26-41] years, and SS genotype was the most frequent (73.5%).
40 The prevalence of eugonadism, compensated, and secondary hypogonadism was
41 67.5%, 26.4%, and 5.88%, respectively. No men with primary hypogonadism were
42 identified in our sample. Those with compensated hypogonadism had also higher
43 FSH levels than individuals with eugonadism; $p < 0.001$). **Conclusion:** In our study
44 population of men with SCD a high prevalence of compensated hypogonadism was
45 identified, which is a controversial and distinct clinical entity that warrants monitoring
46 and further research.

47

48 **Keywords:** sickle cell disease, compensated hypogonadism, testosterone

49

50 INTRODUCTION

51

52 Sickle cell disease (SCD) is a relatively common genetic disease and
53 comprises a group of disorders characterized by the presence of at least one
54 hemoglobin S (1). The sickle gene mutation is common in sub-Saharan Africa and
55 other parts of the world and it is estimated that more than 300 000 children are born
56 each year with SCD, with millions of people currently affected across the globe (2,3),
57 about two-thirds of them in Africa (ref). SCD has been recognized as a public health
58 issue and a neglected problem by several key agencies, including the United Nations
59 (UN) and the World Health Organization (WHO)(4). The chronic morbidity associated
60 with SCD may lead to an increased socioeconomic burden and requires long-term
61 quality of care (5) SCD is commonly associated with the development of
62 hypogonadism, but there is controversy regarding its etiology, mechanisms, and
63 clinical implications (5).

64 Hypogonadism is characterized by impaired testicular function, which may
65 affect spermatogenesis and/or testosterone synthesis. Usually the diagnosis of
66 hypogonadism requires identification of low serum testosterone (T) levels. Individuals
67 with low T levels may be asymptomatic or present with a worse metabolic status,
68 reduced energy, diminished physical performance, fatigue, depression, reduced
69 motivation, poor concentration, infertility, reduced sex drive, erectile dysfunction and
70 increased rates of all-cause mortality (6–8).

71 Although the development of androgen deficiency is currently considered
72 multifactorial, male hypogonadism has been classically classified as
73 hypergonadotropic (primary) or hypogonadotropic (secondary) according to its
74 etiology (9). More recently a new clinical variant of hypogonadism defined as defined

75 as compensated hypogonadism has been proposed, which is characterized by
76 normal T and elevated LH levels. These authors suggested that compensated
77 hypogonadism represents a distinct clinical state, which warrants monitoring despite
78 its unknown etiology and consequences (8). Compensated hypogonadism has also
79 been reported in 3% of patients with male infertility, with similar outcomes of those
80 with primary hypogonadism (9).

81 Multiple theories have been proposed in attempts to explain the
82 hypogonadism related to SCD. Zinc deficiency, socioeconomic factors, constitutional
83 variables, and repetitive vaso-occlusive episodes in the testes and pituitary, are
84 possible explanations though the definite cause remains unknown. Vaso-occlusion is
85 the most widely accepted theory as recurrent microinfarctions in patients with SCD
86 are commonly found in other organs and systems (10). Few studies have been
87 designed to evaluate hormonal abnormalities in men with SCD and a more precise
88 understanding is yet to be accomplished (11).

89 As studies evaluating detailed hormonal profiles in men with SCD are lacking,
90 the aim of this study was to estimate the prevalence of hypogonadism in men with
91 SCD and to characterize its etiology using a more comprehensive classification.

92

93

94 **MATERIALS AND METHODS**

95

96 *Study design and population*

97

98 This was a cross-sectional study involving 34 men with SCD aged 18 or older
99 who were followed up at a local SCD referral center between January and December
100 2019. Men with a history of cryptorchidism, testicular tumors, testicular or inguinal
101 surgery, or with acute onset of testicular at the time of the interview were excluded. A
102 structured questionnaire, including sociodemographic (age, sex, self-reported
103 race/color) and clinical variables (anthropometric measurements, type of
104 hemoglobinopathy, therapy with hydroxyurea or NSAIDs, and the occurrence of
105 priapism), was applied to participants. Anthropometric data (weight and height) were
106 measured and used to calculate the BMI as weight in kilograms divided by height in
107 meters squared (kg/m^2).

108

109 *Hormonal evaluation*

110 Blood samples were collected between 7 and 9 a.m. for the determination of
111 total testosterone (TT), free testosterone (FT), LH, and FSH levels, as well as a
112 complete blood count and hemoglobin electrophoresis. The methods used for the
113 laboratory tests included: hydrodynamic focusing, flow cytometry, SLS-hemoglobin,
114 and Giemsa microscopy for the complete blood count; electrochemiluminescence
115 assays (Atellica IM® analyzer, Siemens Healthcare Diagnostics Inc., Tarrytown, NY,
116 USA) for the determination of T, LH, and FSH levels; an equation involving TT, sex
117 hormone-binding globulin (SHBG), and the association constant of albumin for T,
118 assuming a fixed albumin concentration of 4.3 g/dL, for the calculation of FT(12); and

119 high-performance liquid chromatography (HPLC) and capillary electrophoresis
120 (Capillarys Hemoglobine) for the quantitation of hemoglobin fractions.

121 Subjects were classified into four groups according to T and LH levels(13):
122 men were considered to have eugonadism if $T \geq 300$ ng/dL and $LH \leq 9.4$ mUI/mL;
123 primary hypogonadism was defined as $T < 300$ ng/dL and $LH > 9.4$ mUI/mL;
124 secondary hypogonadism as $T < 300$ ng/dL and $LH \leq 9.4$ mUI/mL; and compensated
125 hypogonadism as $T \geq 300$ ng/dL and $LH > 9.4$ mUI/mL. FSH levels above 7.8 ng/dL
126 were considered elevated (14).

127 All subjects were verbally and individually approached and provided informed
128 consent. This study was approved by our Research Ethics

129

130 *Statistical analysis*

131

132 Quantitative variables were presented as medians and interquartile ranges,
133 while nominal variables were expressed as absolute values, percentages, or
134 fractions. The Mann-Whitney U test was used to compare continuous variables, while
135 the Fisher's test was used to compare categorical variables. A $p < 0.05$ was
136 considered statistically significant, and 95% confidence intervals were presented as a
137 measure of precision. GraphPad Prism, version 8.0.3, San Diego-CA, USA, was
138 used for data analysis.

139

140

141 **RESULTS**

142

143 Our sociodemographic data are detailed in **Table 1**. We assessed 34 men with
144 a median age of 33 years [26-41], most of whom had an SS genotype (73.5%) and
145 were black or brown (94.1%). Five (14.7%) of them were on continuous hydroxyurea
146 therapy and all had been medicated with NSAIDs, with ibuprofen being the most
147 commonly used drug.

148 Fifty percent of patients had LH levels of 5.92 mUI/mL [4.36 – 9.42]. Median
149 FSH levels were 6.01 mUI/mL [4.08 – 8.96], clinical data are detailed in **Table 2**. In
150 our sample, no men were diagnosed with primary hypogonadism, whereas 23
151 (67.6%) were classified as eugonadal and 2 (5.8%) as having secondary
152 hypogonadism. In addition, compensated hypogonadism was identified in 9 men
153 (26.4%) (**Figure 1**).

154 We found no differences regarding SCD genotype, anthropometric
155 measurements, or disease severity between eugonadal men and those with
156 compensated hypogonadism. Median FSH levels among men with compensated
157 hypogonadism were significantly higher than among eugonadal men. The proportion
158 of men with FSH levels above 7.8 mUI/mL was significantly higher among those with
159 compensated hypogonadism ($p < 0.0001$) (**Table 2**).

160

161 **DISCUSSION**

162

163 Gonadal dysfunction, disturbances of the hypothalamic-pituitary-testicular axis,
164 and the etiology of hypogonadism in patients with SCD are controversial issues, and
165 there are still many uncertainties about the pathophysiology of these conditions and

166 their clinical significance(11). We investigated the prevalence of different types of
167 hypogonadism in men with SCD according to the classification described by Tajar et
168 al (2010) in the EMAS. The prevalence of compensated hypogonadism in our sample
169 of men with SCD was 26.4%, a figure considerably higher than those reported in
170 similar studies, 9.5%(13) and 3%(14), respectively.

171 Tajar at al. (2010) were the first to explore the concept of compensated
172 hypogonadism in a study with 3369 community-dwelling men aged 40-79 years from
173 eight European centers. They also introduced the concept that different
174 hypogonadism categories may present with different clinical features. According to
175 this study, sexual complaints were more frequently reported in cases of primary
176 hypogonadism, whereas isolated physical symptoms such as inability to walk long
177 distances or perform brisk physical activity were more common in compensated
178 hypogonadism (8).

179 A retrospective study involving 4173 men with sexual dysfunction by Corona et
180 al., reported that 4.1% of individuals had compensated hypogonadism and were
181 more likely to present with both increased frequency of psychological symptoms,
182 such as anxiety, obsessive-compulsive symptoms, and depression; and increased
183 cardiovascular mortality in comparison to those with primary or secondary
184 hypogonadism. The authors hypothesized that compensated hypogonadism could be
185 a surrogate marker of an underlying disease, rather than a new clinical entity(15).

186 Compensated hypogonadism also appears to be relevant in the elderly. Ucak
187 et al. (2013) conducted a study with 250 men over 70 years of age with compensated
188 hypogonadism and found their T and LH levels to be independently associated with
189 worsening performance of activities of daily living, as well as deteriorating cognitive
190 function, nutritional status, and mood, when compared to healthy controls. The

191 authors concluded androgen and LH levels should be assessed in elderly men, and
192 those diagnosed with compensated hypogonadism should then undergo a physical
193 and neuropsychiatric evaluation (16).

194 The clinical significance of compensated hypogonadism is still poorly
195 understood, but this condition is known to be associated with both aging and an
196 increased frequency of physical symptoms related to testosterone deficiency, but not
197 with sexual complaints, as previously mentioned. These observations and its striking
198 prevalence of 9.5% as reported in the EMAS raise the question of whether this
199 subtype of hypogonadism warrants treatment. In, especially older men, may benefit
200 from the inclusion of LH levels in the initial screening for hypogonadism (17).

201 Studies about compensated hypogonadism and its etiology are controversial
202 and scarce in patients with SCD. Rhodes et al (2009)(18) did not find a statistically
203 significant difference in the testosterone levels of 19 boys with SCD when compared
204 to controls and so they were unable to detect primary hypogonadism. Özen et al.
205 (2013)(19) studied 50 Turkish children aged 4 to 18 years and found, among the 35
206 boys included in the sample, one with hypergonadotropic (primary) hypogonadism
207 and 3 with small testes and low testosterone, but with normal luteinizing hormone
208 (LH) levels, suggesting this condition can be either primary or secondary. Abbasi and
209 colleagues (1976)(20) analyzed hormone levels of 14 patients and found elevated
210 concentrations of LH and follicle-stimulating hormone (FSH), as well as low
211 testosterone (T), suggesting primary hypogonadism. Dada and Nduka (1980)(22)
212 demonstrated reduced LH, FSH, and testosterone levels in 19 men with SCD,
213 findings suggestive of hypothalamic axis dysfunction (secondary hypogonadism),
214 rather than gonadal failure (primary hypogonadism). Martins et al(23) studied some
215 aspects of compensated hypogonadism among 10 men with homozygous SCD.

216 Despite the limited number of patients, the authors referred to compensated
217 hypogonadism as a likely transient condition and considered it a potential state of
218 androgen resistance(23).

219 All subjects with compensated hypogonadism in our sample had FSH levels
220 above 7.8 mU/mL, a threshold previously reported as a predictor of impaired
221 spermatogenesis(24). It is likely that the exocrine compartment might be impaired in
222 while the endocrine compartment might still be enough to sustain appropriate T
223 production. A cross-sectional study with 786 Caucasian-European discussed the
224 concept of compensated hypogonadism among infertile subjects. The authors found
225 that this condition had a similar clinical characteristic to those with primary
226 hypogonadism, and both groups had the worst clinical outcomes in terms of impaired
227 fertility. While this classification was not designed for the setting of male infertility, it
228 could be useful in clinical practice to indicate impaired spermatogenesis(14).

229 It is important to highlight that all men in our sample had history of ibuprofen
230 intake for acute pain episodes. Previous published data indicate a strong association
231 between ibuprofen use and the elevation of LH levels, which might lead to
232 compensated hypogonadism. In a randomized controlled trial including 31 men aged
233 18-35 years who received 600 mg of ibuprofen twice daily for 6 weeks, the authors
234 showed ibuprofen use increased LH levels in 23% after 14 days and 33% after 44
235 days ($p = 0.01$). They also linked ibuprofen use with a reduction in anti-Müllerian
236 hormone levels and postulated this drug would affect steroidogenesis by inhibiting
237 the expression of related genes, thus resulting in HPT axis dysfunction (25).
238 However, this study evaluated solely the impact of short-term course of ibuprofen on
239 hormonal profile, and clinical significance of its effect in the long-term are probably
240 negligible.

241 Although our cohort had only 34 participants, it is one of the largest studies in
242 the scientific literature to evaluate hormonal profiles in men with SCD. We also
243 identified a high prevalence of an underreported and poorly understood condition,
244 which might be of clinical significance for monitoring and counseling patients. The
245 main limitation of this study is perhaps its cross-sectional design, as no definitive
246 explanation for this condition may be given. In addition, this sample came from a
247 specialized center for patients with SCD and may not represent the general
248 population of SCD.

249

250

251 **CONCLUSION**

252

253 A high prevalence of compensated hypogonadism was identified in our sample
254 of men with SCD, which may reflect early testicular injury and may progress to
255 permanent dysfunction. It seems to be more prevalent in young men with SCD than
256 in the general population of older men. Vaso-occlusive phenomena, testicular
257 microinfarctions, changes in the testicular microenvironment, long-term or recurrent
258 ibuprofen use, and genetic aspects might be associated with such findings. Although
259 this clinical entity is not completely understood, continuous monitoring might be
260 useful in preventing or anticipating additional clinical deterioration.

261

262 **Disclosure statement**

263 The authors report no conflicts of interest.

264

265 **Funding**

266 This study received no external funding.

267

268 **Academic affiliation**

269 This paper is part of the master's dissertation of Anna Paloma Martins Rocha Ribeiro,
270 Postgraduate Program in Public Health, State University of Feira de Santana.

271

272

273

274 **REFERENCES**

275

- 276 1. Bunn HF. Pathogenesis and treatment of sickle cell disease. *N Engl J Med.*
277 1997;337(9):762–9.
- 278 2. Wastnedge E, Patel S, Goh MY, Rudan I. The global burden of sickle cell
279 disease in children under five years of age: a systematic review and meta-
280 analysis. *J Glob Health.* 2018;8(2):1–9.
- 281 3. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle
282 Cell Anaemia in Children under Five, 2010 – 2050: Modelling Based on
283 Demographics, Excess Mortality, and Interventions. *PLoS One.* 2013;10(7):1–
284 14.
- 285 4. Mburu J, Odame I. Sickle cell disease: reducing the global disease burden. *Int*
286 *J Lab Hematol.* 2019;41(February):82–8.
- 287 5. Pleasants S. A moving target: migration has led to an increase in the
288 occurrence of sickle-cell disease in countries with previously low incidence of
289 the disorder. *Nature.* 2014;515(11):1–3.
- 290 6. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Bruce J, Chiles KA, et al.
291 Evaluation and Management of Testosterone Deficiency: AUA Guideline. *J*
292 *Urol* [Internet]. 2018; Available from: <https://doi.org/10.1016/j.juro.2018.03.115>
- 293 7. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum
294 testosterone levels in male hypogonadism: Why and when to check — A
295 review. *Int J Clin Pract.* 2017;(August):1–9.
- 296 8. Peterson MD, Belakovskiy A, Mcgrath R, Yarrow JF. Testosterone Deficiency ,
297 Weakness, and Multimorbidity in Men. *Sci Rep* [Internet]. 2018;8(5897):1–9.
298 Available from: <http://dx.doi.org/10.1038/s41598-018-24347-6>
- 299 9. Jungwirth A, Diemer T, Kopa Z, Krausz C, Minhas S, Tournaye H. EAU
300 Guidelines on Male Infertility. Vol. 1, European Association of Urology. 2018.
301 47 p.
- 302 10. Li M, Fogarty J, Whitney KD, Stone P. Repeated testicular infarction in a
303 patient with sickle cell disease: A possible mechanism for testicular failure.
304 *Urology.* 2003;62(3):551.
- 305 11. Huang AW, Muneyyirci-Delale O. Reproductive endocrine issues in men with
306 sickle cell anemia. *Andrology.* 2017;5(4):679–90.
- 307 12. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods

- 308 for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.*
309 1999;84(10):3666–72.
- 310 13. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al. Characteristics
311 of secondary, primary, and compensated hypogonadism in aging men:
312 Evidence from the European male ageing study. *J Clin Endocrinol Metab.*
313 2010;95(4):1810–8.
- 314 14. Ventimiglia E, Ippolito S, Capogrosso P, Pederzoli F, Cazzaniga W, Boeri L, et
315 al. Primary, secondary and compensated hypogonadism: a novel risk
316 stratification for infertile men. *Andrology.* 2017;5(3):505–10.
- 317 15. Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E, et al.
318 Characteristics of compensated hypogonadism in patients with sexual
319 dysfunction. *J Sex Med.* 2014;11(7):1823–34.
- 320 16. Ucak S, Basat O, Karatemiz G. Functional and nutritional state in elderly men
321 with compensated hypogonadism. *J Am Med Dir Assoc.* 2013;14(6):433–6.
- 322 17. Lee JA, Kuchakulla M, Arora H, Kulandavelu S, Gonzalez E, Masterson TA, et
323 al. Age induced nitroso-redox imbalance leads to subclinical hypogonadism in
324 Male mice. *Front Endocrinol (Lausanne).* 2019;10(MAR):1–6.
- 325 18. Rhodes M, Akohoue SA, Shankar SM, Fleming I, An A, Yu C, et al. Growth
326 Patterns in Children with Sickle Cell Anemia during Puberty. *Pediatr Blood*
327 *Cancer.* 2009;53(4):635–41.
- 328 19. Özen S, Ünal S, Erçetin N, Taşdelen B. Frequency and Risk Factors of
329 Endocrine Complications in Turkish Children and Adolescents with Sickle Cell
330 Anemia. *Turk J Hematol.* 2013;30:25–31.
- 331 20. Abbasi AA, Prasad AS, Ortega J, Congco E, Oberleas D. Gonadal Function
332 Abnormalities in Sickle Cell Anemia Studies in Adult Male Patients. *Ann Intern*
333 *Med.* 1976;85:601–5.
- 334 21. Dada OA, Nduka EU. Endocrine function and haemoglobinopathies: Relation
335 between the sickle cell gene and circulating plasma levels of testosterone,
336 luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males.
337 *Clin Chim Acta.* 1980;105(2):269–73.
- 338 22. Dada O, Nduka E. Endocrine function and haemoglobinopathies: relation
339 between the sickle cell gene and circulating plasma levels of testosterone,
340 luteinising hormone (LH) and follicle stimulating hormone(FSH) in adult males.
341 *Clin Chim Acta.* 1980;105:269–73.

- 342 23. Martins PRJ, De Vito FB, Resende GAD, Kerbauy J, Pereira G de A, Moraes-
343 Souza H, et al. Male sickle cell patients, compensated transpubertal
344 hypogonadism and normal final growth. *Clin Endocrinol (Oxf)*. 2019;91(5):676–
345 82.
- 346 24. Barbotin AL, Ballot C, Sigala J, Ramdane N, Duhamel A, Marcelli F, et al. The
347 serum inhibin B concentration and reference ranges in normozoospermia. *Eur*
348 *J Endocrinol*. 2015;172(6):669–76.
- 349 25. Kristensen DM, Desdoits-Lethimonier C, Mackey AL, Dalgaard MD, De Masi F,
350 Munkbøl CH, et al. Ibuprofen alters human testicular physiology to produce a
351 state of compensated hypogonadism. *Proc Natl Acad Sci U S A*.
352 2018;115(4):E715–24.
353

354

Variables	n (34)	%
SCD genotype		
Homozygous HbSS	25	73.5
Heterozygous SC/SB-thal	9	26.5
Self-reported race/color		
Black	21	61.8
Brown	11	32.4
Yellow	1	2.9
Indigenous	1	2.9
Hydroxyurea therapy		
No	29	85.3
Yes	5	14.7
NSAIDs use		
No	0	0
Yes	34	100
Education level		
Primary education	7	20.6
Secondary education	20	58.8
Higher education	7	20.6
Occupation		
Active ^a	6	17.7
Inactive ^b	28	82.3
History of priapism		
Yes	18	52.9

355 Table 1 – Sociodemographic and clinical data of men with SCD.

356

357 **Table 2** – Anthropometric and laboratory data of men with SCD

Variables	Median [p25-p75]*
Weight (kg)	61.5 [56.3 – 67.3]
Height (m)	1.7 [1.64 – 1.75]
BMI (kg/m ²)	21.6 [19.2 – 23.8]
Hemoglobin (g/dL)	9.75 [8.05 – 12.0]
Total testosterone (ng/dL)	582.9 [428.8 – 685.9]
Free testosterone (ng/dL)	9.85 [8.07 – 11.37]
LH (mUI/mL)	5.92 [4.36 – 9.42]
FSH (mUI/mL)	6.01 [4.08 – 8.96]

358 *Data are expressed as medians and interquartile ranges (25th and 75th percentiles)

359

360 **Table 3** – Clinical, anthropometric, and laboratory data of eugonadal men with SCD in
361 comparison to those with compensated hypogonadism.

Variables	Eugonadism (n = 23)	Compensated hypogonadism (n = 9)	p value
Homozygous HbSS (%)	16 (69%)	7 (77%)	0.943
Age (years)	34 [27 – 41]	33 [22-41]	0.612
Hydroxyurea therapy (%)	6 (26%)	0 (0%)	0.153
History of priapism (%)	4 (44%)	12 (48%)	0.162
BMI (kg/m ²)	21.6 [18.9-23.9]	21.7 [19.7-22.9]	0.991
Hemoglobin (g/dL)	9.8 [8.5-12.1]	9.3 [7.6-11.4]	0.331
FSH (mUI/mL)	5.37 [3.7-6.3]	9.5 [9.0-23.8]	< 0.0001*
FSH > 7,8 (%)	5 (21.7%)	9 (100%)	< 0.0001*

362 *Statistically significant differences

363 BMI: body mass index; FSH: follicle-stimulating hormone; LH: luteinizing hormone.

364

